$SGRY
Surgery Partners, Inc.

2023 Q2 Form 10-Q Financial Statement

#000163883323000070 Filed on May 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $667.6M $666.2M
YoY Change 8.48% 11.74%
Cost Of Revenue $491.7M $510.8M
YoY Change 6.75% 13.16%
Gross Profit $175.9M $155.4M
YoY Change 13.63% 7.32%
Gross Profit Margin 26.35% 23.33%
Selling, General & Admin $53.00M $53.40M
YoY Change 14.47% 7.88%
% of Gross Profit 30.13% 34.36%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $24.40M $33.70M
YoY Change -12.86% 22.99%
% of Gross Profit 13.87% 21.69%
Operating Expenses $76.20M $619.8M
YoY Change -85.86% 25.01%
Operating Profit $99.70M $46.40M
YoY Change 30.33% -53.78%
Interest Expense -$45.10M -$46.80M
YoY Change -20.74% -16.87%
% of Operating Profit -45.24% -100.86%
Other Income/Expense, Net $6.500M $0.00
YoY Change
Pretax Income $49.90M -$400.0K
YoY Change 154.59% -100.91%
Income Tax -$7.800M -$1.600M
% Of Pretax Income -15.63%
Net Earnings $18.90M -$24.90M
YoY Change -202.72% -304.1%
Net Earnings / Revenue 2.83% -3.74%
Basic Earnings Per Share $0.15 -$0.20
Diluted Earnings Per Share $0.15 -$0.20
COMMON SHARES
Basic Shares Outstanding 126.5M shares 126.0M shares
Diluted Shares Outstanding 127.4M shares 125.2M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.4M $245.5M
YoY Change -21.99% -35.21%
Cash & Equivalents $177.4M $245.5M
Short-Term Investments
Other Short-Term Assets $112.6M $69.40M
YoY Change 136.55% 37.15%
Inventory $70.30M $71.80M
Prepaid Expenses $39.30M $29.30M
Receivables $449.9M $452.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $810.2M $868.9M
YoY Change 2.77% -7.27%
LONG-TERM ASSETS
Property, Plant & Equipment $1.093B $1.118B
YoY Change 2.47% 5.87%
Goodwill $4.236B $4.217B
YoY Change 6.08% 7.43%
Intangibles
YoY Change
Long-Term Investments $192.2M $191.6M
YoY Change 20.35% 102.75%
Other Assets $233.8M $118.6M
YoY Change 79.02% -1.17%
Total Long-Term Assets $5.810B $5.774B
YoY Change 5.58% 7.88%
TOTAL ASSETS
Total Short-Term Assets $810.2M $868.9M
Total Long-Term Assets $5.810B $5.774B
Total Assets $6.621B $6.643B
YoY Change 5.23% 5.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $131.5M $144.4M
YoY Change 4.03% 17.49%
Accrued Expenses $192.3M $196.2M
YoY Change -16.68% -14.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $64.70M $62.90M
YoY Change -5.27% -7.5%
Total Short-Term Liabilities $458.6M $475.1M
YoY Change -12.1% -12.39%
LONG-TERM LIABILITIES
Long-Term Debt $2.505B $2.531B
YoY Change -17.04% -16.34%
Other Long-Term Liabilities $346.3M $80.20M
YoY Change 259.23% -16.28%
Total Long-Term Liabilities $2.851B $80.20M
YoY Change 2857.57% -16.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $458.6M $475.1M
Total Long-Term Liabilities $2.851B $80.20M
Total Liabilities $4.602B $555.3M
YoY Change 644.6% -12.98%
SHAREHOLDERS EQUITY
Retained Earnings -$563.3M -$582.3M
YoY Change 10.69% 18.72%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.018B $1.962B
YoY Change
Total Liabilities & Shareholders Equity $6.621B $6.643B
YoY Change 5.23% 5.63%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $18.90M -$24.90M
YoY Change -202.72% -304.1%
Depreciation, Depletion And Amortization $24.40M $33.70M
YoY Change -12.86% 22.99%
Cash From Operating Activities $52.10M $74.50M
YoY Change 23.75% -6.64%
INVESTING ACTIVITIES
Capital Expenditures $25.80M $24.30M
YoY Change -215.18% 33.52%
Acquisitions $40.70M
YoY Change 30.87%
Other Investing Activities -$45.40M $4.100M
YoY Change -59.43% -55.91%
Cash From Investing Activities -$71.20M -$70.70M
YoY Change -46.98% 50.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $15.90M
YoY Change -6.47%
Cash From Financing Activities -49.00M -$41.20M
YoY Change -17.37% -5.72%
NET CHANGE
Cash From Operating Activities 52.10M $74.50M
Cash From Investing Activities -71.20M -$70.70M
Cash From Financing Activities -49.00M -$41.20M
Net Change In Cash -68.10M -$37.40M
YoY Change -55.05% 240.0%
FREE CASH FLOW
Cash From Operating Activities $52.10M $74.50M
Capital Expenditures $25.80M $24.30M
Free Cash Flow $26.30M $50.20M
YoY Change -59.22% -18.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001638833
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2023Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2023Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations
CY2023Q1 us-gaap Oci Cash Flow Hedge Reclassification For Discontinuance Statement Of Income Or Comprehensive Income Extensible Enumeration
OciCashFlowHedgeReclassificationForDiscontinuanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#InterestIncomeExpenseNonoperatingNet
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37576
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Surgery Partners, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3620923
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
340 Seven Springs Way, Suite 600
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Brentwood
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37027
CY2023Q1 dei City Area Code
CityAreaCode
615
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
234-5900
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
SGRY
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126476669 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
245500000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
282900000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
452900000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
456300000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
71800000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
71400000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
29300000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
31400000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
69400000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79000000.0 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
868900000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
921000000.0 usd
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
382700000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
374300000 usd
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
844300000 usd
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
876600000 usd
CY2023Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
4252600000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
4179400000 usd
CY2023Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
191600000 usd
CY2022Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
190300000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
274000000.0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
279100000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
93300000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
91500000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118600000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144200000 usd
CY2023Q1 us-gaap Assets
Assets
6643300000 usd
CY2022Q4 us-gaap Assets
Assets
6682100000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
144400000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
151600000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
67800000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
68900000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
200000000.0 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
210100000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
62900000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
62800000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
475100000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
493400000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2530900000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2559000000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
268800000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
271400000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
80200000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
75400000 usd
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
345800000 usd
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
342000000.0 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20310000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20310000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126480483 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126480483 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125960834 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125960834 shares
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1300000 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1300000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2478100000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2478000000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
64900000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
76200000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-582300000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-557300000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1962000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1998200000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
980500000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
942700000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2942500000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2940900000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6643300000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6682100000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
666200000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
596200000 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
202200000 usd
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
178900000 usd
CY2023Q1 us-gaap Supplies Expense
SuppliesExpense
188400000 usd
CY2022Q1 us-gaap Supplies Expense
SuppliesExpense
171600000 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
74600000 usd
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
63600000 usd
CY2023Q1 sgry Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
21400000 usd
CY2022Q1 sgry Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
20000000.0 usd
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
45600000 usd
CY2022Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
37300000 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
532200000 usd
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
471400000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32000000.0 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29500000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33700000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27400000 usd
CY2023Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
12500000 usd
CY2022Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
7100000 usd
CY2023Q1 sgry Grant Revenue
GrantRevenue
1100000 usd
CY2022Q1 sgry Grant Revenue
GrantRevenue
1200000 usd
CY2023Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
-10500000 usd
CY2022Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
100000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3300000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3100000 usd
CY2023Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3000000.0 usd
CY2022Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
32800000 usd
CY2023Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
300000 usd
CY2022Q1 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
-2400000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
619800000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
495800000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
46400000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
100400000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-46800000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-56300000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-400000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
44100000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1600000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1200000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
42800000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
26100000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
30600000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24900000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
12200000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125206000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87995000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125206000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90272000 shares
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1200000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
42800000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-11300000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
56800000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10100000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
99600000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
26100000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
30600000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36200000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
69000000.0 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1969600000 usd
CY2022Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
32200000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7700000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
56800000 usd
CY2022Q1 sgry Non Controlling Interest Acquisitions And Disposals Of Interests Held By Non Controlling Interest Holders Net
NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
-29100000 usd
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
24600000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2012600000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2940900000 usd
CY2023Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-6700000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3700000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11300000 usd
CY2023Q1 sgry Non Controlling Interest Acquisitions And Disposals Of Interests Held By Non Controlling Interest Holders Net
NonControllingInterestAcquisitionsAndDisposalsOfInterestsHeldByNonControllingInterestHoldersNet
46100000 usd
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
30200000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2942500000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
1200000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
42800000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33700000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27400000 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
9000000.0 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
8600000 usd
CY2023Q1 sgry Noncash Interest Income Expense Net
NoncashInterestIncomeExpenseNet
-6500000 usd
CY2022Q1 sgry Noncash Interest Income Expense Net
NoncashInterestIncomeExpenseNet
-6100000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4200000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3700000 usd
CY2023Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
-10500000 usd
CY2022Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
100000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1800000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1000000.0 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
200000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
900000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8800000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000.0 usd
CY2023Q1 sgry Increase Decrease In Medicare Accelerated Payments And Deferred Governmental Grants
IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
-1200000 usd
CY2022Q1 sgry Increase Decrease In Medicare Accelerated Payments And Deferred Governmental Grants
IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredGovernmentalGrants
-18000000.0 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-3800000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-7200000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
74500000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
79800000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24300000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18200000 usd
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
40700000 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
31100000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
8000000.0 usd
CY2022Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 usd
CY2023Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
9600000 usd
CY2022Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 usd
CY2023Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0 usd
CY2022Q1 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
11500000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
4100000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
9300000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70700000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47100000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
15900000 usd
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
17000000.0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
15900000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11900000 usd
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1300000 usd
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
CY2023Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
41900000 usd
CY2022Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
36200000 usd
CY2023Q1 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
5100000 usd
CY2022Q1 us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
-3100000 usd
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-3100000 usd
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
700000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41200000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-43700000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37400000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11000000.0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282900000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
389900000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
245500000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378900000 usd
CY2023Q1 sgry Number Of Surgical Facilities Owned
NumberOfSurgicalFacilitiesOwned
145 facility
CY2023Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
31 state
CY2023Q1 sgry Number Of Surgical Facilities Owned Majority Interest
NumberOfSurgicalFacilitiesOwnedMajorityInterest
92 facility
CY2023Q1 sgry Number Of Surgical Facilities Owned Consolidated
NumberOfSurgicalFacilitiesOwnedConsolidated
118 facility
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. Actual results could differ from those estimates.</span></div>
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
666200000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
596200000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
4.000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.029
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
-1800000 usd
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
-4600000 usd
CY2022Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1800000 usd
CY2022Q1 us-gaap Income Tax Reconciliation Disposition Of Business
IncomeTaxReconciliationDispositionOfBusiness
-1000000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4137100000 usd
CY2023Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
91300000 usd
CY2023Q1 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
11100000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4217300000 usd
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
342000000.0 usd
CY2021Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
330200000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
7800000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
10600000 usd
CY2023Q1 sgry Redeemable Noncontrolling Interest Increase Decrease From Redemptions Or Purchase Of Interests
RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
7700000 usd
CY2022Q1 sgry Redeemable Noncontrolling Interest Increase Decrease From Redemptions Or Purchase Of Interests
RedeemableNoncontrollingInterestIncreaseDecreaseFromRedemptionsOrPurchaseOfInterests
12300000 usd
CY2023Q1 sgry Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders
RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
11700000 usd
CY2022Q1 sgry Redeemable Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders
RedeemableNoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
11600000 usd
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
345800000 usd
CY2022Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
341500000 usd
CY2023Q1 sgry Grant Revenue
GrantRevenue
1100000 usd
CY2022Q1 sgry Grant Revenue
GrantRevenue
1200000 usd
CY2022Q4 sgry Unrecognized Grant Funds Received
UnrecognizedGrantFundsReceived
3000000 usd
CY2022Q1 sgry Coronavirus Aid Relief And Economic Security Act Cares Act Government Grant Received Repayments
CoronavirusAidReliefAndEconomicSecurityActCARESActGovernmentGrantReceivedRepayments
18000000 usd
CY2023Q1 sgry Variable Interest Entity Number Of Facilities
VariableInterestEntityNumberOfFacilities
7 facility
CY2023Q1 sgry Variable Interest Entity Number Of Facilities
VariableInterestEntityNumberOfFacilities
5 physician_practice
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
553500000 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
585700000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
9700000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
10200000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
2593800000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
2621800000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
62900000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
62800000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2530900000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2559000000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
274000000.0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
279100000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
490600000 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
529600000 usd
CY2023Q1 sgry Lease Right Of Use Asset
LeaseRightOfUseAsset
764600000 usd
CY2022Q4 sgry Lease Right Of Use Asset
LeaseRightOfUseAsset
808700000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000000.0 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
36500000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
268800000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
271400000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
306800000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
307900000 usd
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
21400000 usd
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
20900000 usd
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
532100000 usd
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
564800000 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
553500000 usd
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
585700000 usd
CY2023Q1 sgry Lease Liability
LeaseLiability
860300000 usd
CY2022Q4 sgry Lease Liability
LeaseLiability
893600000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
16400000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
16100000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9400000 usd
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9200000 usd
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
12300000 usd
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
9900000 usd
CY2023Q1 sgry Finance Lease Cost
FinanceLeaseCost
21700000 usd
CY2022Q1 sgry Finance Lease Cost
FinanceLeaseCost
19100000 usd
CY2023Q1 sgry Variable And Short Term Lease Cost
VariableAndShortTermLeaseCost
5200000 usd
CY2022Q1 sgry Variable And Short Term Lease Cost
VariableAndShortTermLeaseCost
4400000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
43300000 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
39600000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
16100000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
15600000 usd
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
11700000 usd
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
9800000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6400000 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6000000.0 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8900000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22000000.0 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
15400000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
89300000 usd
CY2023Q1 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1366100000 usd
CY2022Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1518200000 usd
CY2023Q1 us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
-33600000 usd
CY2023Q1 us-gaap Derivative Asset Notional Amount
DerivativeAssetNotionalAmount
85200000 usd
CY2023Q1 us-gaap Derivative Liability Notional Amount
DerivativeLiabilityNotionalAmount
34500000 usd
CY2022Q4 us-gaap Derivative Asset Notional Amount
DerivativeAssetNotionalAmount
113400000 usd
CY2022Q4 us-gaap Derivative Liability Notional Amount
DerivativeLiabilityNotionalAmount
40400000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Reclassification For Discontinuance Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
5400000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Reclassification For Discontinuance Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax
5300000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66700000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24900000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
12200000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125206000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87995000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125206000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90272000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000000.0 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
200000000.0 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
38000000.0 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
36500000 usd
CY2023Q1 srt Payables To Customers
PayablesToCustomers
30000000.0 usd
CY2022Q4 srt Payables To Customers
PayablesToCustomers
31900000 usd
CY2023Q1 sgry Cost Report Liabilities Current
CostReportLiabilitiesCurrent
24200000 usd
CY2022Q4 sgry Cost Report Liabilities Current
CostReportLiabilitiesCurrent
23500000 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
23700000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
19400000 usd
CY2023Q1 sgry Acquisition Escrow Liability Current
AcquisitionEscrowLiabilityCurrent
17400000 usd
CY2022Q4 sgry Acquisition Escrow Liability Current
AcquisitionEscrowLiabilityCurrent
28800000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
210100000 usd
CY2023Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
22100000 usd
CY2022Q4 us-gaap Self Insurance Reserve
SelfInsuranceReserve
20800000 usd
CY2023Q1 us-gaap Estimated Insurance Recoveries
EstimatedInsuranceRecoveries
12700000 usd
CY2022Q4 us-gaap Estimated Insurance Recoveries
EstimatedInsuranceRecoveries
12700000 usd
CY2022Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
32800000 usd
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 segment
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
666200000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
596200000 usd
CY2023Q1 sgry Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
90100000 usd
CY2022Q1 sgry Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
77100000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-400000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
44100000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
26100000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
30600000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-46800000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-56300000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
33700000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27400000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4200000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3700000 usd
CY2023Q1 sgry Business Combination Integration Related Costs And Merger Costs
BusinessCombinationIntegrationRelatedCostsAndMergerCosts
12800000 usd
CY2022Q1 sgry Business Combination Integration Related Costs And Merger Costs
BusinessCombinationIntegrationRelatedCostsAndMergerCosts
7100000 usd
CY2023Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
-10500000 usd
CY2022Q1 sgry Gain Loss On Disposition Of Assets And Deconsolidation
GainLossOnDispositionOfAssetsAndDeconsolidation
100000 usd
CY2023Q1 sgry Gain Loss Related To Litigation Settlement And Regulatory Change Impact
GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact
-8000000.0 usd
CY2022Q1 sgry Gain Loss Related To Litigation Settlement And Regulatory Change Impact
GainLossRelatedToLitigationSettlementAndRegulatoryChangeImpact
30800000 usd
CY2023Q1 sgry Undesignated Derivative Activity
UndesignatedDerivativeActivity
-600000 usd
CY2022Q1 sgry Undesignated Derivative Activity
UndesignatedDerivativeActivity
0 usd
CY2023Q1 sgry Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
90100000 usd
CY2022Q1 sgry Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
77100000 usd
CY2023Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
12500000 usd
CY2022Q1 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
7100000 usd
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
300000 usd
CY2023Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-3000000 usd
CY2022Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
32800000 usd
CY2023Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
600000 usd
CY2022Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
2000000 usd
CY2023Q1 sgry Interest Expense Impact Of Change In Letter Of Protection Regulation
InterestExpenseImpactOfChangeInLetterOfProtectionRegulation
4400000 usd
CY2023Q1 us-gaap Assets
Assets
6643300000 usd
CY2022Q4 us-gaap Assets
Assets
6682100000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24300000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18200000 usd

Files In Submission

Name View Source Status
0001638833-23-000070-index-headers.html Edgar Link pending
0001638833-23-000070-index.html Edgar Link pending
0001638833-23-000070.txt Edgar Link pending
0001638833-23-000070-xbrl.zip Edgar Link pending
a2023q1exhibit311.htm Edgar Link pending
a2023q1exhibit312.htm Edgar Link pending
a2023q1exhibit321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgry-20230331.htm Edgar Link pending
sgry-20230331.xsd Edgar Link pending
Show.js Edgar Link pending
sgry-20230331_cal.xml Edgar Link unprocessable
sgry-20230331_lab.xml Edgar Link unprocessable
sgry-20230331_def.xml Edgar Link unprocessable
sgry-20230331_pre.xml Edgar Link unprocessable
sgry-20230331_htm.xml Edgar Link completed